Biogen has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash, expanding its portfolio of rare-disease medicines.
In this article
Biogen
has agreed to acquire Apellis Pharmaceuticals
for about $5.6 billion in cash, expanding its portfolio of rare-disease medicines, the companies said on Tuesday.
The deal marks Biogen’s push to bolster growth as revenue from its multiple sclerosis drugs wanes and as it seeks to build a broader rare-disease portfolio, including an expansion into kidney disease treatments.
BioMarin Pharmaceutical said on Friday it would acquire Amicus Therapeutics for about $4.8 billion, expanding its presence in…
The Italian firm Angelini Pharma is buying Catalyst Pharmaceuticals, the maker of rare disease drugs, for $4.1 billion.
Gilead Sciences said on Monday it will buy cancer therapy partner Arcellx for an implied equity value of $7.8 billion.
Neurocrine has offered $53 per Soleno share held, which represents a premium of about 34% to the stock's last close.
Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in vivo…
Eli Lilly said on Monday it would buy privately held blood cancer treatment developer Ajax Therapeutics for up to $2.3 billion…
